Minapharm Pharmaceuticals results, Q1 2023
Net profit, assets, equity and cash flow for Q1 2023, against the same period a year earlier, from the published financial statements.
Net profit49.93 millionEGP · −61.7% vs the same period a year earlier
Total assets8.12 billionEGP · +67.0% vs the same period a year earlier
Shareholders' equity3.4 billionEGP · +53.2% vs the same period a year earlier
Operating cash flow139 millionEGP · −44.9% vs the same period a year earlier
In short
- Minapharm Pharmaceuticals's net profit for Q1 2023 was about 49.93 million EGP, down −61.7% from 131 million EGP in Q1 2022.
- Total assets at the end of Q1 2023 were about 8.12 billion EGP, and shareholders' equity about 3.4 billion EGP.
- Operating cash flow for Q1 2023 was positive at 139 million EGP.
Key lines against the same period a year earlier
This periodQ1 2022Change
Net profit49.93 million131 million−61.7%
Gross profit340 million338 million+0.4%
Total assets8.12 billion4.86 billion+67.0%
Total liabilities4.72 billion2.64 billion+78.5%
Shareholders' equity3.4 billion2.22 billion+53.2%
Total liabilities and equity8.12 billion4.86 billion+67.0%
Operating cash flow139 million253 million−44.9%
Investing cash flow-589 million-158 million−274.2%
Financing cash flow569 million245 million+132.4%
Net change in cash119 million340 million−65.0%
Figures in EGP from the published statement summaries (consolidated where the company publishes consolidated statements), after normalising reporting units across periods. The exact figure is in the attached report, which may be the standalone version. Figures are as shown in the published statement summary; quarterly figures may be cumulative from the start of the fiscal year.
Minapharm Pharmaceuticals's Q3 2026 results, the day they are published
One email on the day, no account, and a one-click stop in the email itself.
By subscribing you agree to receive these alerts only. Privacy policy